BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...migration of CLL cells ( No. 1837 ), and knocking out the cell surface proteoglycan SDC1...
...lectin like receptor 2 PIEZO1 - Piezo-type mechanosensitive ion channel component 1 SDC1 (CD138) - Syndecan 1...
BioCentury | Jul 18, 2018
Distillery Techniques

Drug platforms

...growth factor and bone morphogenic protein families, and the surface adhesion molecules are syndecan 1 (SDC1; CD138...
...5 (LAMA5) Platelet derived growth factor BB (PDGFBB) Serpin peptidase inhibitor clade F member 2 (SERPINF2) Syndecan 1 (SDC1) (CD138) Syndecan...
BioCentury | Mar 21, 2017
Clinical News

Scripps researchers design new ADCs

...Kadcyla ado-trastuzamab emtansine, or vehicle. In a xenograft mouse model of multiple myeloma, an anti- CD138...
...increase yield. Mary Romeo The Scripps Research Institute Epidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) Syndecan 1 (SDC1) (CD138...
BioCentury | Dec 6, 2016
Clinical News

PVX-410: Ph Ib started

...CS1) Description: Cancer vaccine targeting XBP1, cell-surface glycoprotein CS1 and syndecan 1 ( SDC1 ; CD138...
...response Status: Phase Ib started Milestone: NA Alicia Parker PVX-410 OncoPep Inc. SLAM family member 7 (SLAMF7) (CS1) Syndecan 1 (SDC1) (CD138) X-box...
BioCentury | Dec 6, 2016
Clinical News

Durvalumab: Ph Ib started

...cell-surface glycoprotein SLAM family member 7 ( SLAMF7 ; CS1) and syndecan 1 ( SDC1 ; CD138...
BioCentury | Dec 1, 2016
Clinical News

PVX-410: Ph Ib started

...CS1) Description: Cancer vaccine targeting XBP1, cell-surface glycoprotein CS1 and syndecan 1 ( SDC1 ; CD138...
...Phase Ib started Milestone: NA Alicia Parker PVX-410 Dana-Farber Cancer Institute OncoPep Inc. SLAM family member 7 (SLAMF7) (CS1) Syndecan 1 (SDC1) (CD138) X-box...
BioCentury | Dec 1, 2016
Clinical News

Durvalumab: Ph Ib started

...cell-surface glycoprotein SLAM family member 7 ( SLAMF7 ; CS1) and syndecan 1 ( SDC1 ; CD138...
BioCentury | Aug 27, 2015
Distillery Therapeutics

Therapeutics: Syndecan 4 (SDC4)

Inflammation INDICATION: Asthma Mouse studies suggest inhibiting SDC4 could help treat asthma. In a mouse model of ovalbumin-induced asthma, SDC4 knockout, or treatment before or after asthma onset with an antibody that inhibits SDC4 formation,...
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: X-box binding protein 1 (XBP1)

...have PVX-410 , a vaccine targeting XBP1, cell-surface glycoprotein CS1 and syndecan 1 ( SDC1 ; CD138...
BioCentury | May 28, 2015
Targets & Mechanisms

Joint attack

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants. The...
Items per page:
1 - 10 of 36